1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. CStone Pharmaceuticals
  6. News
  7. Summary
    2616   KYG2588M1006

CSTONE PHARMACEUTICALS

(2616)
  Report
Delayed Hong Kong Stock Exchange  -  03/31 04:08:07 am EDT
5.040 HKD   -9.84%
05/17CStone announces final PFS analysis of a registrational study of sugemalimab in patients with stage III NSCLC further demonstrates its robust efficacy and significant clinical benefits shown in interim
AQ
05/16CStone Pharmaceuticals Announces Final PFS Analysis of Registrational Study of Sugemalimab in Patients with Stage III NSCLC
CI
04/28CStone to present the latest clinical results of anti-PD-L1 antibody sugemalimab and anti-PD-1 antibody nofazinlimab at ASCO 2022
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

EQRx, Inc. and CStone Pharmaceuticals Announce Sugemalimab Demonstrates Statistically Significant Overall Survival Benefit in Patients with Stage IV Non-Small Cell Lung Cancer

01/19/2022 EDT

EQRx, Inc. along with its partner CStone Pharmaceuticals, announced that sugemalimab plus chemotherapy demonstrated a statistically significant improvement in overall survival (OS) compared to placebo plus chemotherapy as a first-line treatment for patients with Stage IV non-small cell lung cancer (NSCLC) in the randomized, double-blind Phase 3 GEMSTONE-302 study. These data were reported after a planned interim analysis for OS, a key secondary endpoint of the study. These results build on previously presented positive data from the GEMSTONE-302 study, which met the primary endpoint of progression-free survival (PFS) and were recently published in The Lancet Oncology. Clinical benefit was observed across subgroups, including patients with squamous and non-squamous subtypes, and regardless of PD-L1 expression levels. As previously reported, the safety profile of sugemalimab was consistent with that of the PD-1/PD-L1 class.


© S&P Capital IQ 2022
All news about CSTONE PHARMACEUTICALS
05/17CStone announces final PFS analysis of a registrational study of sugemalimab in patient..
AQ
05/16CStone Pharmaceuticals Announces Final PFS Analysis of Registrational Study of Sugemali..
CI
04/28CStone to present the latest clinical results of anti-PD-L1 antibody sugemalimab and an..
AQ
04/22CStone Announces Results From Phase 3 AGILE Data of TIBSOVO
AQ
04/21CStone Pharmaceuticals Announces Publication of Results from the Phase 3 Agile Trial of..
CI
04/13CStone Announces Presentation of Preclinical data on a Multi-Specific Antibody-based Th..
AQ
04/12CStone Pharma Presents Immunotherapy Candidate's Preclinical Data at US Oncology Confer..
MT
04/12CStone Pharmaceuticals Announces Presentation of Preclinical Data on A Multi-Specific A..
CI
03/31CStone announces first patient enrollment in the U.S. in the Phase 1 clinical trial of ..
AQ
03/30CStone Pharmaceuticals Announces First Patient Enrollment in the U.S. in the Phase 1 Cl..
CI
More news
Financials
Sales 2021 260 M 41,1 M 41,1 M
Net income 2021 -1 683 M -266 M -266 M
Net cash 2021 1 387 M 219 M 219 M
P/E ratio 2021 -
Yield 2021 -
Capitalization 4 755 M 749 M 750 M
EV / Sales 2021 12,9x
EV / Sales 2022 5,16x
Nbr of Employees 573
Free-Float 75,4%
Chart CSTONE PHARMACEUTICALS
Duration : Period :
CStone Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 4,08 CNY
Average target price 9,32 CNY
Spread / Average Target 128%
EPS Revisions
Managers and Directors
Ning Jun Jiang Chairman & Chief Executive Officer
Jian Xin Yang Chief Medical Officer & Senior Vice President
Xin Zhong Wang Chief Scientific Officer & Senior Vice President
Ting Yuk Wu Independent Non-Executive Director
Hong Bin Sun Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
CSTONE PHARMACEUTICALS-39.06%748
GILEAD SCIENCES, INC.-12.93%79 298
REGENERON PHARMACEUTICALS, INC.4.38%71 026
VERTEX PHARMACEUTICALS14.91%64 540
WUXI APPTEC CO., LTD.-19.12%41 409
BIONTECH SE-39.08%38 169